Niosomes in sustained and targeted drug delivery: Some recent advances

Journal of Drug Targeting

Volumn 17, Issue 9, 2009, Pages 671-689

  Azeem, Adnan ^a   Anwer, Md Khalid ^a,b   Talegaonkar, Sushama ^a  

^a HAMDARD UNIVERSITY   (India)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

drug targeting; Niosomes; nonionic surfactants; sustained drug delivery

Indexed keywords

ACETAZOLAMIDE; BETA CAROTENE; CAMPTOTHECIN; CHOLESTEROL; COLCHICINE; COSMETIC; DITHRANOL; DNA VACCINE; DOXORUBICIN; ENOXACIN; FINASTERIDE; FLUOROURACIL; FLURBIPROFEN; FUROSEMIDE; GLYCEROL; IBUPROFEN; INSULIN; KETOROLAC TROMETAMOL; MINOXIDIL; NIOSOME; NONIONIC SURFACTANT; PIROXICAM; POLYSORBATE; RETINOIC ACID; RIBAVIRIN; SORBITAN ESTER; STIBOGLUCONATE SODIUM; SUMATRIPTAN; SURFACTANT; DRUG CARRIER; LIPOSOME;

ACNE; ALOPECIA; ATHEROSCLEROSIS; BIOCOMPATIBILITY; BIODEGRADABILITY; BIOFILM; COSMETIC INDUSTRY; DENSITY GRADIENT; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SYNTHESIS; DRUG TARGETING; EMULSION; EVAPORATION; FLUIDIZATION; GLAUCOMA; GOUT; HEPATITIS B; HUMAN; HYDRATION; HYDROPHILICITY; HYDROPHOBICITY; HYPERTENSION; INFLAMMATION; LEISHMANIASIS; MEMBRANE PERMEABILITY; MIGRAINE; NEOPLASM; OSMOSIS; PH; PRIORITY JOURNAL; PSORIASIS; REVIEW; SKIN CANCER; SKIN INFECTION; SOFT TISSUE INFECTION; T CELL LYMPHOMA; TRANSMISSION ELECTRON MICROSCOPY; ULTRASOUND; VIRUS INFECTION; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; METHODOLOGY;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; SURFACE-ACTIVE AGENTS;

EID: 73449102914     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611860903079454     Document Type: Review

References (105)

1. Abd-Elbary A, El-Laithy HM, Tadros MI. (2008). Sucrose stearatebased proniosome-derived niosomes for the nebulisable delivery of cromolyn sodium. Int J Pharm, 357, 189-198.
2. Agarwal R, Katare OP, Vyas SP. (2001). Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm, 228, 43-52. (Pubitemid 32905364)
3. Aggarwal D, Garg A, Kaur IP. (2004). Development of a topical niosomal preparation of acetazolamide: preparation and evaluation. J Pharm Pharmacol, 56, 1509-1517. (Pubitemid 39601991)
4. Alcantar N, Dearborn K, VanAuker M, Toomey R, Hood E. (2008). Niosome-Hydrogel Drug Delivery. US Patent Application 20080050445.
5. Alsarra IA. (2008). Evaluation of proniosomes as an alternative strategy to optimize piroxicam transdermal delivery. J Microencapsulation, 11, 1-7.
6. Alsarra IA, Bosela AA, Ahmed SM, Mahrous GM. (2005). Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur J Pharm Biopharm, 59, 485-490. (Pubitemid 40342523)
7. Arien A, Dupuy B. (1997). Encapsulation of calcitonin in liposomes depends in the vesicle preparation method. J Microencapsulation, 14, 753-760. (Pubitemid 27483093)
8. Arunothayanun P, Uchegbu IF, Florence AT. (1999). Osmotic behaviour of polyhedral non-ionic surfactant vesicles (niosomes). J Pharm Pharmacol, 51, 651-657. (Pubitemid 29346705)
9. Azeem A, Jain N, Iqbal Z, Ahmad FJ, Aqil M, Talegaonkar S. (2008a). Feasibility of proniosomes based transdermal delivery of frusemide: formulation optimization and pharmacotechnical evaluation. Pharm Dev Technol, 13, 155-163. (Pubitemid 351465726)
10. Azeem A, Ahmad FJ, Khan ZI, Talegaonkar S. (2008b). Non-ionic surfactant vesicles as a carrier for transdermal delivery of frusemide. J Dispersion Sci Technol, 29, 723-730. (Pubitemid 351584083)
11. Azeem A, Khan ZI, Aqil M, Ahmad FJ, Khar RK, Talegaonkar S. (2009). Microemulsions as a surrogate carrier for dermal drug delivery. Drug Dev Ind Pharm, 35, 525-547.
12. Azmin MN, Florence AT, Handjani-Vila RM, Stuart JFB, Vanlerberghe G, Whittaker JS. (1985). The effect of niosomes entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol, 37, 237-242. (Pubitemid 15149834)
13. Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. (1985). The preparation and properties of niosomes-non ionic surfactant vesicles. J Pharm Pharmacol, 37, 863-868.
14. Baillie AJ, Coombs GH, Dolan TF. (1986). Non-ionic surfactant vesicles, niosomes, as delivery system for the anti- leishmanial drug, sodium stribogluconate. J Pharm Pharmacol, 38, 502-505. (Pubitemid 16081869)
15. Bangham AD, Standish MM, Watkins JC. (1965). Diffusion of univalent ions across the swollen phospholipids. J Mol Biol, 13, 238-252.
16. Begley DJ. (1996). The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol, 48, 136-146. (Pubitemid 26129083)
17. Blazek-Welsh AI, Rhodes DG. (2001). SEM imaging predicts quality of niosomes from maltrodextrin based proniosomes. Pharm Res, 18, 656-661. (Pubitemid 32595795)
18. Cable C, Cassidy J, Kaye SB, Florence AT. (1988). Doxorubicin in cholesteryl polyoxyethylene modified niosomes. Evidence of enhancement of absorption in mice. J Pharm Pharmacol, 40, 31P.
19. Caddeo C, Teskac K, Sinico C, Kristl J. (2008). Effect of resveratrol incorporated in liposomes on proliferation and UV-B protection of cells. Int J Pharm, 363, 183-191.
20. Carafa M, Santucci E, Lucania G. (2002). Lidocaine-loaded non-ionic surfactant vesicles: characterization and in vitro permeation studies. Int J Pharm, 231, 21-32. (Pubitemid 33086815)
21. Carter KC, Dolan TF, Alexander T, Baillie AJ, McColgan C. (1989). Visceral leishmaniasis: drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishamnia donovani infected BaLB/c mice. J Pharm Pharmacol, 41, 87-91. (Pubitemid 19109540)
22. Carter KC, Baillie AJ, Williams DM. (1999). Vesicle formulation. US Patent 5,869,091.
23. Choi MJ, Maibach HI. (2005). Liposomes and niosomes as topical drug delivery systems. Skin Pharmacol Physiol, 18, 209-219. (Pubitemid 41159952)
24. Cosco D, Celia C, Cilurzo F, Trapasso E, Paolino D. (2008). Colloidal carriers for the enhanced delivery through the skin. Expert Opin Drug Deliv, 5, 737-755.
25. Desai TR, Finlay WH. (2002). Nebulization of niosomal all-transretinoic acid: an inexpensive alternative to conventional liposomes. Int J Pharm, 241, 311-317. (Pubitemid 34718032)
26. Devaraj GN, Parakh SR, Devraj R, Apte SS, Rao BR, Rambhau D. (2002). Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol. J Colloid Interface Sci, 251, 360-365. (Pubitemid 34775403)
27. Devi SG, Venkatesh, Udupa N. (2000). Niosomal sumatriptan succinate for nasal administration. Ind J Pharm Sci, 62, 479-481.
28. Domschke S, Domschke W, Bloom SR, Mitznegg P, Mitchell SJ, Lux G, Strunz U. (1978). Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects. Gut, 19, 1049-1053. (Pubitemid 9037608)
29. Dufes C, Gaillard F, Uchegbu IF, Schatzlein AG, Olivier JC, Muller JM. (2004). Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain. Int J Pharm, 285, 77-85. (Pubitemid 39361538)
30. Elsayed MMA, Abdallah OY, Naggar VF, Khalafallah NM. (2006). Deformable liposomes and ethosomes: mechanism of enhanced drug delivery. Int J Pharm, 322, 60-66. (Pubitemid 44348860)
31. Fang JY, Yu SY, Wu PC, Huang YB, Tsai YH. (2001a). In vitro skin permeation of estradiol from various proniosome formulations. Int J Pharm, 215, 91-99.
32. Fang JY, Hong CT, Chiu WT, Wang YY. (2001b). Effect of liposomes and niosomes on skin permeation of enoxacin. Int J Pharm, 219, 61-72.
33. Frokjaer S, Hjorth EL, Worts O. (1984). Liposome Technology (Vol.1, pp. 235-245). Boca Raton, FL, CRC Press Inc.
34. Garg A, Tisdale AW, Haidari E, Kokkoli E. (2009). Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin- mimetic peptide. Int J Pharm, 366, 201-210.
35. Gozes I, Bardea A, Reshef A, Zamostiano R, Zhukovsky S, Rubinraut S, Fridkin M, Brenneman DE. (1996). Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc Natl Acad Sci USA, 93, 427-432. (Pubitemid 26041486)
36. Guinedi AS, Mortada ND, Mansour S, Hathout RM. (2005). Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm, 306, 71-82. (Pubitemid 41643141)
37. Gupta A, Prajapati SK, Balamurugan M, Singh M, Bhatia D. (2007). Design and development of a proniosomal transdermal drug delivery system for captopril. Tropical J Pharm Res, 6, 687-693.
38. Gupta PN, Mishra V, Rawat A, Dubey P, Mahor S, Jain S, Chatterji DP, Vyas SP. (2005). Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: a comparative study. Int J Pharm, 293, 73-82. (Pubitemid 40381082)
39. Handjani-Vila RM, Ribier A, Rondot B, Vanlerberghe G. (1979). Dispersions of lamellar phases of non-ionic lipids in cosmetic products. Int J Cosmetic Sci, 1, 303-314. (Pubitemid 10125800)
40. Hao Y, Zhao F, Li N, Yang Y, Li K. (2002). Studies on a high encapsulation of colchicine by a noisome system. Int J Pharm, 244, 73-80. (Pubitemid 35245447)
41. Hassan M, Refai E, Andersson M, Schnell PO, Jacobsson H. (1994). In vivo dynamical distribution of 131I-VIP in the rat studied by gamma-camera. Nucl Med Biol, 21, 865-872. (Pubitemid 24263580)
42. Hofland HEJ, Boustra JA, Verhoef JC, Buckton G, Chowdry BZ, Ponec M, Junginger HE. (1992). Safety aspects of non-ionic surfactant vesicles- a toxicity study related to the physicochemical characteristics of non-ionic surfactants. J Pharm Pharmacol, 44, 287-294.
43. Hofland HEJ, Boustra JA, Ponec M, Bodde HE, Spies F, Coos VJ, Junginger HE. (1999). Interactions of non-ionic surfactant vesicles with cultured keratinocytes and human skin in vitro: a survey of toxicological aspects and ultrastructural changes in stratum corneum. J Control Release, 16, 155-168.
44. Hood E, Strom JA, VanAuker M. (2006). Ultrasound Enhancement of Drug Release Across Non-Ionic Surfactant Membranes. US Patent Application 20060292211.
45. Hood E, Gonzalez M, Plaas A, Strom J, VanAuker M. (2007). Immunotargeting of nonionic surfactant vesicles to inflammation. Int J Pharm, 339, 222-230. (Pubitemid 46977592)
46. Hu C, Rhodes DG. (1999). Proniosomes: a novel drug carrier preparation. Int J Pharm, 185, 23-35. (Pubitemid 29333093)
47. Jain S, Singh P, Mishra V, Vyas SP. (2005). Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against Hepatitis B. Immunol Lett, 101, 41-49. (Pubitemid 41297497)
48. Katanasaka Y, Ida T, Asai T, Maeda N, Oku N. (2008). Effective delivery of an angiogenesis inhibitor by neovessel targeted liposomes. Int J Pharm, 360, 219-224.
49. Kaur IP, Garg A, Singla AK, Aggarwal D. (2004). Vesicular systems in ocular delivery: an overview. Int J Pharm, 269, 1-14. (Pubitemid 38035207)
50. Khandare JN, Madhavi G, Tamhankar BM. (1994). Niosomes novel drug delivery system. The Eastern Pharmacist, 37, 61-64.
51. Kiwada H, Niimura H, Fujisaki Y, Yamada S, Kato Y. (1985). Application of synthetic alkyl glycoside vesicles as drug carriers. Chem Pharm Bull, 33, 753-759.
52. Kumar SK, Jain SK, Pancholi SS, Agarwal S, Saraf DK, Agarwal GP. (2003). Provesicular transdermal drug delivery system of ethinylestradiol and levonorgestrel for contraception and hormone replacement therapy. Indian J Pharm Sci, 65, 620-627.
53. Leli'vre V, Pineau N, Du J, Wen CH, Nguyen T, Janet T, Muller JM, Waschek JA. (1998). Differential effects of peptide histidine isoleucine (PHI) and related peptides on stimulation and suppression of neuroblastoma cell proliferation. J Biol Chem, 273, 19685-19690. (Pubitemid 28367026)
54. Lippman SM, Kessler JF, Meyskens FL. (1987). Retinoids as preventive and therapeutic anticancer agents. Cancer Treat Rep, 71, 493-515. (Pubitemid 17103260)
55. Liu T, Guo R. (2007). Structure and transformation of the niosome prepared from PEG 6000/Tween 80/Span 80/H2O lamellar liquid crystal. Colloids Surf A, 295, 130-134. (Pubitemid 46187015)
56. Liu T, Guo R, Hua W, Qiu J. (2007). Structure behaviors of hemoglobin in PEG 6000/Tween 80/Span 80/H2O niosome system. Colloids Surf A, 293, 255-261. (Pubitemid 44940868)
57. Lokshin A, Zhang H, Mayotte J, Lokshin M, Levitt ML. (1999). Early effects of retinoic acid on proliferation, differentiation and apoptosis in non-small cell lung cancer cell line. Anticancer Res, 19, 5251-5254. (Pubitemid 30103357)
58. Magistretti PJ, Morrison JH, Shoemaker WJ, Sapin V, Bloom FE. (1981). Vasoactive intestinal polypeptide induces glycogenolysis in mouse cortical slices: a possible regulatory mechanism for the local control of energy metabolism. Proc Natl Acad Sci USA, 78, 6535-6539. (Pubitemid 12208177)
59. Manconi M, Sinico C, Valenti D, Loy G, Fadda AM. (2002). Niosomes as carriers for tretinoin. I. Preparation and properties. Int J Pharm, 234, 237-248. (Pubitemid 34142628)
60. Manconi M, Valenti D, Sinico C, Lai F, Loy G, Fadda AM. (2003). Niosomes as carriers for tretinoin II. Influence of vesicular incorporation on tretinoin photostability. Int J Pharm, 260, 261-272. (Pubitemid 36773923)
61. Manconi M, Sinico C, Valenti D, Lai F, Fadda AM. (2006). Niosomes as carriers for tretinoin III. A study into the in vitro cutaneous delivery of vesicle-incorporated tretinoin. Int J Pharm, 311, 11-19.
62. Manosroi A, Jantrawut P, Manosroi J. (2008). Antiinflammatory activity of gel containing novel elastic niosomes entrapped with diclofenac diethylammonium. Int J Pharm, 360, 156-163.
63. Maver LD, Bally MB, Hope MJ, Cullis PR. (1985). Biochem Biophys Acta, 816, 294-302.
64. Mayer LD, Bally MB, Hope MJ, Cullis PR. (1985). Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochem Biophys Acta, 816, 294-302. (Pubitemid 15047328)
65. Mayne ST. (1996). Beta-carotene, carotenoids and disease prevention in humans. FASEB J, 10, 690-701. (Pubitemid 26172815)
66. Mokhtar M, Sammour OA, Hammad MA, Megrab NA. (2008). Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Int J Pharm, 361, 104-111.
67. Mukherjee B, Patra B, Layek B, Mukherjee A. (2007). Sustained release of acyclovir from nano-liposomes and nano-niosomes. Int J Nanomedicine, 2, 213-225. (Pubitemid 47215022)
68. Muller RH, Radtke M, Wissing SA. (2002). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev, 54, 131-155.
69. Mura S, Pirot F, Manconi M, Falson F, Fadda AM. (2007). Liposomes and niosomes as potential carriers for dermal delivery of minoxidil. J Drug Target, 15, 101-108. (Pubitemid 46957695)
70. Murdan S, Gregoriadis G, Florence AT. (1999). Sorbitan monostearate/ polysorbate 20 organogels containing niosomes: a delivery vehicle for antigens? Eur J Pharm Sci, 8, 177-185. (Pubitemid 29324645)
71. Namdeo A, Jain NK. (1999). Niosomal delivery of 5-fluorouracil. J Microencapsulation, 16, 731-740. (Pubitemid 29478952)
72. Ning M, Guo Y, Pan H, Chen X, Gu Z. (2005). Preparation, in vitro and in vivo evaluation of liposomal/niosomal gel delivery systems for clotrimazole. Drug Dev Ind Pharm, 31, 375-383. (Pubitemid 41289150)
73. Ogiso T, Niinaka N, Iwaki M. (1996). Mechanism for enhancement effect of lipid disperse system on percutaneous absorption. J Pharm Sci, 85, 57-64. (Pubitemid 26029626)
74. Palozza P, Muzzalupo R, Trombino S, Valdannini A, Picci N. (2006). Solubilization and stabilization of β -carotene in niosomes: delivery to cultured cells. Chem Phys Lipids, 139, 32-42. (Pubitemid 41796992)
75. Paolino D, Cosco D, Muzzalupo R, Trapasso E, Picci N, Fresta M. (2008). Innovative bola surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. Int J Pharm, 353, 233-242.
76. Pardakhty A, Varshosaz J, Rouholamini A. (2007). In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int J Pharm, 328, 130-141. (Pubitemid 44895483)
77. Rai K, Gupta Y, Jain A, Jain SK. (2008). Transferosomes: self optimizing carriers for bioactives. PDA J Pharm Sci Technol, 62, 362-379.
78. Rao Y, Zheng F, Zhang X, Gao J, Liang W. (2008). In vitro percutaneous permeation and skin accumulation of finasteride using vesicular ethosomal carriers. AAPS Pharm Sci Tech, 9, 860-865.
79. Reddy DR, Udupa N. (1993). Formation and evaluation of oral and transdermal preparations of flurbiprofen and piroxicam incorporated with different carriers. Drug Dev Ind Pharm, 19, 843-852. (Pubitemid 23111976)
80. Rentel CO, Bouwstra JA, Naisbett B, Junginger HE. (1999). Niosomes as a novel peroral vaccine delivery system. Int J Pharm, 186, 161-167. (Pubitemid 29459043)
81. Rogerson A, Cummings J, Willmott N, Florence AT. (1988). The distribution of doxorubicin in mice following administration in niosomes. J Pharm Pharmacol, 40, 337-342.
82. Ruckmani K, Jayakar B, Ghosal SK. (2000). Nonionic surfactant vesicles (niosomes) of cytarabine hydrochloride for effective treatment of leukemias: encapsulation, storage and in vitro release. Drug Dev Ind Pharm, 26, 217-222. (Pubitemid 30111645)
83. Saettone MF, Perini G, Carafa M, Santucci E, Alhaique F. (1996). Nonionic surfactant vesicles as ophthalmic carriers for cyclopentolate. A preliminary evaluation. STP Pharma Sci, 6, 94-98.
84. Schreier H, Bouwstra J. (1994). Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery. J Control Release, 30, 1-15. (Pubitemid 24173173)
85. Shahiwala A, Misra A. (2002). Studies in topical application of niosomally entrapped nimesulide. J Pharm Pharmaceut Sci, 5, 220-225. (Pubitemid 37211713)
86. Shi B, Fang C, Pei Y. (2006). Stealth PEG-PHDCA niosomes: effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity. J Pharm Sci, 95, 1873-1887. (Pubitemid 44433020)
87. Solanki AB, Parikh JR, Parikh RH. (2007). Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level box-behnken design. AAPS Pharm Sci Tech, 8, E1-E7.
88. Solanki AB, Parikha J, Parikh R. (2008). Preparation, characterization, optimization, and stability studies of aceclofenac proniosomes. Iranian J Pharm Res, 7, 237-246.
89. Tabbakhian M, Tavakoli N, Jaafari MR, Daneshamouz S. (2006). Enhancement of follicular delivery of finasteride by liposomes and niosomes 1. In vitro permeation and in vivo deposition studies using hamster flank and ear models. Int J Pharm, 323, 1-10. (Pubitemid 44397357)
90. Talsma H, Steenbergen MJV, Borchert JCH, Crommelin DJA. (1994). A novel technique for the one-step preparation of liposomes and non ionic surfactant vesicles without the use of organic solvents. Liposome formation in a continuous gas stream: the "bubble" method. J Pharm Sci, 83, 276-280. (Pubitemid 24224195)
91. Uchegbu IF, Vyas SP. (1998). Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm, 172, 33-70. (Pubitemid 28430243)
92. Uchegbu IF, Bouwstra JA, Florence AT. (1992). Large disc-shaped structures (discomes) in non ionic surfactant vesicle to micelle transitions. J Phys Chem, 96, 10548-10553.
93. Uchegbu IF, Duncan R. (1997). Niosomes containing N-(2-hydroxypropyl) methacrylamide copolymer-doxorubicin (PK1): effect of method of preparation and choice of surfactant on niosome characteristics and a preliminary study of body distribution. Int J Pharm, 155, 7-17. (Pubitemid 27368117)
94. Varshosaz J, Pardakhty A, Mohsen S, Baharanchi H. (2005). Sorbitan monopalmitate-based proniosomes for transdermal delivery of chlorpheniramine maleate. Drug Dev, 12, 75-82. (Pubitemid 40315361)
95. Vora B, Khopade AJ, Jain NK. (1998). Proniosome based transdermal delivery of levonorgestrel for effective contraception. J Control Release, 54, 149-165. (Pubitemid 28342694)
96. Vyas SP, Khar RK. (2002). Niosomes, Targeted and Controlled Drug Delivery, Novel Carrier Systems (1st ed., pp. 249-279). New Delhi: CBS Publishers.
97. Vyas SP, Mysore N, Jaitely V, Venkatesan N. (1998). Discoidal niosome based controlled ocular delivery of timolol maleate. Pharmazie, 53, 466-469. (Pubitemid 28338283)
98. Vyas SP, Singh RP, Jain S, Mishra V, Mahor S, Singh P, Gupta PN, Rawat A, Dubey P. (2005). Non-ionic surfactant based vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis B. Int J Pharm, 296, 80-86. (Pubitemid 40693375)
99. Weiner AL. (1994). Liposomes for protein delivery: selecting manufacture and development processes. Immuno Methods, 4, 201-209. (Pubitemid 24318702)
100. Werle M, Takeuchi H. (2009). Chitosan aprotinin coated liposomes for oral peptide delivery: development, characterization and in vivo evaluation. Int J Pharm, 370, 26-32.
101. Yoshida H, Lehr CM, Kok W, Junginger HE, Verhoef JC, Bouwistra JA. (1992). Niosomes for oral delivery of peptide drugs. J Control Release, 21, 145-153.
102. Yoshioka T, Sternberg B, Florence AT. (1994). Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan triester (Span 85). Int J Pharm, 105, 1-6. (Pubitemid 24087666)
103. Zheng X, Lu J, Deng L, Xiong Y, Chen J. (2009). Preparation and characterization of magnetic cationic liposome in gene delivery. Int J Pharm, 366, 211-217.
104. Zhu L, Huo Z, Wang L, Tong X, Xiao Y, Ni K. (2009). Targeted delivery of methotrexate to skeletal muscular tissue by thermosensitive magnetoliposomes. Int J Pharm, 370, 136-143.
105. Zuidam NJ, Lee SSL, Crommelin DJA. (1993). Sterilization of liposomes by heat treatment. Pharm Res, 10, 1591-1596. (Pubitemid 23325661)